Corient Private Wealth
DGX icon

Corient Private Wealth’s Quest Diagnostics DGX Stock Holding History

Corient Private Wealth’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.56M Sell
39,325
-163,017
-81% -$31.7M 0.01% 715
2025
Q4 		$12.4M Buy
202,342
+176,195
+674% +$32.1M 0.01% 704
2025
Q3 		$4.98M Buy
26,147
+1,142
+5% +$203K 0.01% 712
2025
Q2 		$4.49M Sell
25,005
-9,292
-27% -$1.61M 0.01% 731
2025
Q1 		$5.8M Sell
34,297
-4,204
-11% -$691K 0.01% 650
2024
Q4 		$5.81M Sell
38,501
-225
-0.6% -$35K 0.01% 657
2024
Q3 		$6.01M Sell
38,726
-23
-0.1% -$3.44K 0.01% 698
2024
Q2 		$5.3M Buy
38,749
+734
+2% +$101K 0.01% 693
2024
Q1 		$5.06M Sell
38,015
-3,398
-8% -$441K 0.01% 704
2023
Q4 		$5.71M Buy
41,413
+5,308
+15% +$698K 0.01% 670
2023
Q3 		$4.4M Sell
36,105
-3,799
-10% -$506K 0.01% 662
2023
Q2 		$5.61M Sell
39,904
-38,531
-49% -$5.31M 0.01% 598
2023
Q1 		$11.1M Buy
78,435
+67,635
+626% +$9.68M 0.03% 418
2022
Q4 		$1.69M Buy
+10,800
New +$1.55M 0.01% 758

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Corient Private Wealth's DGX Position: Q1 2026 in Review

Corient Private Wealth reduced its Quest Diagnostics (DGX) stake by 81% in Q1 2026, selling an estimated $31.7M and leaving 39,325 shares worth $7.56M. The position accounts for 0.01% of the portfolio, ranked #715.

Corient Private Wealth first reported a position in DGX in Q4 2022 and has held it in 14 quarters since. The position peaked at $12.4M in Q4 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Corient Private Wealth held 39,325 shares of Quest Diagnostics worth $7.56M as of Q1 2026.
  • Corient Private Wealth sold 163,017 Quest Diagnostics shares in Q1 2026, an estimated $31.7M.
  • Quest Diagnostics made up 0.01% of Corient Private Wealth's portfolio in Q1 2026, its #715 holding.
  • Corient Private Wealth first reported a position in Quest Diagnostics in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's Quest Diagnostics position peaked at $12.4M in Q4 2025.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.